



April 25, 2013

The Honorable Sara Gelser, Chair  
Oregon House of Representatives  
Education Committee  
Salem, Oregon

**RE: Support of SB 611 A**

Dear Rep. Gelser:

Sanofi, a global, diversified healthcare and life sciences company, supports SB 611 as amended, and encourages its passage in a form that reflects a consensus among all interested parties.

Up to six million Americans may be at risk for anaphylaxis, including a large number of children. Eight percent, or one in 12 children, have a food allergy – up 18 percent from 1997 to 2007. The increasing prevalence of allergies and anaphylaxis among children should compel state policymakers to ensure that epinephrine is available in schools through right-to-carry protections and in-school supplies for emergency circumstances involving undiagnosed students or students without immediate access to their own prescription medicine.

Sanofi has very recently begun to offer a new epinephrine auto-injector, Auvi-Q. It is our hope that this new device along with important changes to public policy regarding in-school access to epinephrine therapy, such as those provided in this legislation, will effectively lower the risks of anaphylaxis-related mortality in our nation's student population.

I apologize that I am not able to attend the April 29 hearing in person. However, should you have any questions, my telephone number is (206)320-0536 and my e-mail is [Deanne.Calvert@Sanofi.com](mailto:Deanne.Calvert@Sanofi.com).

Best regards,

A handwritten signature in black ink that reads "Deanne Calvert".

Deanne Calvert  
Sanofi US  
Director, State Government Affairs